Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1980 Nov;10(5):519–524. doi: 10.1111/j.1365-2125.1980.tb01798.x

Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine.

R A Ahmad, H J Rogers
PMCID: PMC1430153  PMID: 7437265

Abstract

1 Seven normal volunteers received oral doses of 100 mg dapsone (DDS), 25 mg pyrimethamine (PYR) singly or in combination in random order. 2 Plasma and salivary DDS and plasma monoacetyldapone (MADDS) and PYR were estimated simultaneously by a hitherto unpublished quantitative absorption thin layer chromatographic method. This assay was shown to be satisfactory for pharmacokinetic studies. 3 The half-life of DDS was unaltered by PYR but the apparent volume of distribution was significantly increased from a mean of 1.53 1 kg-1 to 1.93 1 kg-1 and the peak DDS plasma levels measured fell by 17%. 4 The pharmacokinetic parameters of PYR were unchanged by DDS. 5 The half-life of MADDS was unchanged by PYR and was not affected by the acetylator status of the subject. 6 Salivary DDS excretion reflects the free plasma DDS concentration. Administration of PYR with DDS significantly alters the mean saliva/plasma DDS ratio from 0.265 to 0.358 suggesting an increase in free DDS with PYR therapy. 7 In vitro studies of plasma protein DDS binding indicate that DDS binds to a single class of binding sites on human plasma protein and PYR competitively displaces DDS from these sites. 8 The usefulness of salivary drug measurements in detecting increases of free drug in plasma in man is demonstrated.

Full text

PDF
519

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad R. A., Rogers H. J. Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method. Eur J Clin Pharmacol. 1980 Feb;17(2):129–133. doi: 10.1007/BF00562621. [DOI] [PubMed] [Google Scholar]
  2. Cavallito J. C., Nichol C. A., Brenckman W. D., Jr, Deangelis R. L., Stickney D. R., Simmons W. S., Sigel C. W. Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. Drug Metab Dispos. 1978 May-Jun;6(3):329–337. [PubMed] [Google Scholar]
  3. Coffey J. J., Bullock F. J., Schoenemann P. T. Numerical solution of nonlinear pharmacokinetic equations: effects of plasma protein binding on drug distribution and elimination. J Pharm Sci. 1971 Nov;60(11):1623–1628. doi: 10.1002/jps.2600601106. [DOI] [PubMed] [Google Scholar]
  4. DeAngelis R. L., Simmons W. S., Nichol C. A. Quantitative thin-layer chromatography of pyrimethamine and related diaminopyrimidines in body fluids and tissues. J Chromatogr. 1975 Mar 19;106(1):41–49. doi: 10.1016/s0021-9673(01)81045-1. [DOI] [PubMed] [Google Scholar]
  5. Fried J., Zietz S. Curve fitting by spline and Akima methods: possibility of interpolation error and its suppression. Phys Med Biol. 1973 Jul;18(4):550–558. doi: 10.1088/0031-9155/18/4/306. [DOI] [PubMed] [Google Scholar]
  6. Gelber R., Peters J. H., Gordon G. R., Glazko A. J., Levy L. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225–238. doi: 10.1002/cpt1971122part1225. [DOI] [PubMed] [Google Scholar]
  7. Gibaldi M., McNamara P. J. Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol. 1978 Jul 30;13(5):373–380. doi: 10.1007/BF00644611. [DOI] [PubMed] [Google Scholar]
  8. Glazko A. J., Dill W. A., Montalbo R. G., Holmes E. L. A new analytical procedure for dapsone. Application to blood-level and urinary-excretion studies in normal men. Am J Trop Med Hyg. 1968 May;17(3):465–473. [PubMed] [Google Scholar]
  9. Israili Z. H., Cucinell S. A., Vaught J., Davis E., Lesser J. M., Dayton P. G. Studies of the metabolism of dapsone in man and experimental animals: formation of N-hydroxy metabolites. J Pharmacol Exp Ther. 1973 Oct;187(1):138–151. [PubMed] [Google Scholar]
  10. Jones C. R., Ovenell S. M. Determination of plasma concentrations of dapsone, monoacetyl dapsone and pyrimethamine in human subjects dosed with maloprim. J Chromatogr. 1979 Jun 11;163(2):179–185. doi: 10.1016/s0378-4347(00)81461-9. [DOI] [PubMed] [Google Scholar]
  11. Peters J. H., Gordon G. R., Ghoul D. C., Tolentino J. G., Walsh G. P., Levy L. The diposition of the antileprotic drug dapsone (DDS) in Philippine subjects. Am J Trop Med Hyg. 1972 Jul;21(4):450–457. doi: 10.4269/ajtmh.1972.21.450. [DOI] [PubMed] [Google Scholar]
  12. Reidenberg M. M., Drayer D., DeMarco A. L., Bello C. T. Hydralazine elimination in man. Clin Pharmacol Ther. 1973 Nov-Dec;14(6):970–977. doi: 10.1002/cpt1973146970. [DOI] [PubMed] [Google Scholar]
  13. SMITH C. C., IHRIG J. Persistent excretion of pyrimethamine following oral administration. Am J Trop Med Hyg. 1959 Jan;8(1):60–62. doi: 10.4269/ajtmh.1959.8.60. [DOI] [PubMed] [Google Scholar]
  14. SMITH C. C., SHCMIDT L. H. Observations on the absoroption of pyrimethamine from the gastrointestinal tract. Exp Parasitol. 1963 Apr;13:178–185. doi: 10.1016/0014-4894(63)90068-7. [DOI] [PubMed] [Google Scholar]
  15. Weber M. C., de Clarke V., Harwin R. M., Shiff C. J. An extended field trial of pyrimethamine combined with dapsone in the prophylaxis of malaria. Cent Afr J Med. 1975 Sep;21(9):187–192. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES